Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: Protective effect of defibrotide

Blood

Volumn 100, Issue 1, 2002, Pages 334-340

  Eissner, Günther ^a   Multhoff, Gabriele ^a   Gerbitz, Armin ^a   Kirchner, Silvia ^a   Bauer, Sonja ^a   Haffner, Silvia ^a   Sondermann, Daniela ^a   Andreesen, Reinhard ^a   Holler, Ernst ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DEFIBROTIDE; EPIDERMAL GROWTH FACTOR; FLUDARABINE; HYDROCORTISONE; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ALLOGENIC BONE MARROW TRANSPLANTATION; APOPTOSIS; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; ENDOTHELIUM CELL; EPITHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL;

EID: 0036659926     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.1.334     Document Type: Article

References (38)

1. Holler E, Kolb HJ, Möller A, et al. Increased serum levels of tumor necrosis factor α precede major complications of bone marrow transplantation. Blood. 1990;75:1011-1016.
2. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992;80:2964-2968.
3. Ferrara JL, Levy R, Chao NJ. Pathophysiological mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant. 1999;5:347-356.
4. Xun CQ, Brown BA, Jennings CD, Henslee-Downey PJ, Thompson JS. Acute graft-versushost-like diseases induced by transplantation of human activated natural killer cells into SCID mice. Transplantation. 1993;56:409-417.
5. Weiner RS, Bortin MM, Gale RP, et al. Interstitial pneumonitis after bone marrow transplantation: assessment of risk factors. Ann Intern Med. 1986;104:168-175.
6. Weiss MA. Novel treatment strategies in chronic lymphocytic leukemia. Curr Oncol Rep. 2001;3:217-222.
7. Wasch R, Reisser S, Hahn J, et al. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transplant. 2000;26:243-250.
8. Carella AM, Champlin R, Slavin S, McSweeney P, Storb R. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant. 2000;25:345-350.
9. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
10. Holler E, Kolb HJ, Hiller E, et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood. 1989;73:2018-2024.
11. Eissner G, Kohlhuber F, Grell M, et al. Critical involvement of transmembrane TNF-α in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin. Blood. 1995;86:4184-4193.
12. Lindner H, Holler E, Ertl B, et al. Peripheral blood mononuclear cells induce programmed cell death in human endothelial cells and may prevent repair: role of cytokines. Blood. 1997;89:1931-1938.
13. Haimovitz-Friedman A, Balaban N, Mcloughlin M, et at. Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis. Cancer Res. 1994;54:2591-2597.
14. Fuks Z, Persaud RS, Alfieri A, et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res. 1994;54:2582-2590.
15. Eissner G, Lindner H, Behrends U, et al. Influence of bacterial endotoxin on radiation-induced activation of human endothelial cells in vitro and in vivo: protective role of IL-10. Transplantation. 1996;62:819-827.
16. Lindner H, Holler E, Gerbitz A, Johnson JP, Bornkamm GW, Eissner G. Influence of bacterial endotoxin on radiation-induced activation of human endothelial cells in vitro and in vivo: 2. IL-10 protects against transendothelial migration. Transplantation. 1997;64:1370-1973.
17. Beelen DW, Haralambie E, Brandt H, et al. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood. 1992;80:2668-2676.
18. Eissner G, Multhoff G, Holler E. Influence of bacterial endotoxin on the allogenicity of human endothelial cells. Bone Marrow Transplant. 1998;21:1286-1287.
19. Ades EW, Candal FJ, Swerlick RA, et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol. 1992;99:683-690.
20. Cotter TG, Lennon SV, Glynn JM, Green DR. Microfilament-disrupting agents prevent the formation of apoptotic bodies in tumor cells undergoing apoptosis. Cancer Res. 1992;52:997-1005.
21. Lee A, Whyte MK, Haslett C. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol. 1993;54:283-288.
22. Westphal JR, Tax WJ, Willems HW, Koene RA, Ruiter DJ, De-Waal RM. Accessory function of endothelial cells in anti-CD3-induced T-cell proliferation: synergism with monocytes. Scand J Immunol. 1992;35:449-457.
23. MacDonald HR, Engers HD, Cerrottini JC, Brunner KT. Generation of cytotoxic T lymphocytes in vitro. J Exp Med. 1974;140:718-722.
24. Long E. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol. 1999;17:875-904.
25. Nagler A, Aker M, Or R, et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol. 2001;29:362-370.
26. Michallet M, Bilger K, Garban F, et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol. 2001;19:3340-3349.
27. Hildebrandt G, Bertz H, Mestan A, et al. Analysis of pulmonary function after allogeneic bone marrow transplantation (BMT) or blood stem cell transplantation (PBSCT) using conditioning regimens with total body irradiation (TBI) and conventional intensity compared to regimens without TBI with reduced intensity [abstract]. Bone Marrow Transplant. 2001;27(suppl 1):S216.
28. Bornhauser M, Thiede C, Schuler U, et al. Dosereduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplant. 2000;26:119-125.
29. Huang P, Siciliano MJ, Plunkett W. Gene deletion, a mechanism of induced mutation by arabinosyl nucleosides. Mutat Res. 1989;210:291-301.
30. Genini D, Budihardio I, Plunkett W, et al. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J Biol Chem. 2000;275:29-34.
31. Biederman BC, Pober JS. Human vascular endothelial cells favor clonal expansion of unusual alloreactive CTL. J Immunol. 1999;162:7022-7030.
32. Briscoe DM, Alexander AI, Lichtman AH. Interactions between T lymphocytes and endothelial cells in allograft rejection. Curr Opin Immunol. 1998;10:525-531.
33. Pegram AA, Kennedy LD. Prevention and treatment of veno-occlusive disease. Ann Pharmacother. 2001;35:935-942.
34. Rossini G, Pompilio G, Biglioli P, et al. Protectant activity of defibrotide in cardioplegia followed by ischemia/reperfusion injury in the isolated rat heart. J Card Surg. 1999;14:334-341.
35. Rossini G, Berti F, Trento F, et al. Defibrotide normalizes cardiovascular function hampered by established atherosclerosis in the rabbit. Thromb Res. 2000;97:29-38.
36. Pogliani EM, Perseghin P, Parma M, Pioltelli P, Corneo G. Defibrotide in recurrent thrombotic thrombocytopenic purpura. Clin Appl Thromb Hemost. 2000;6:69-70.
37. San T, Moini H, Emerk K, Bilsel S. Protective effect of defibrotide on perfusion induced endothelial damage. Thromb Res. 2000;99:335-341.
38. Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionateuse study. Br J Haematol. 2000;111:1122-1129.